Tirzepatide and NAD+ Together: What Is Known
Tirzepatide and NAD+ taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 3 results, 2 Oct 2026).
Side by side
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | Tirzepatide | NAD+ |
|---|---|---|
| Class | GLP-1 / GIP dual agonist | Coenzyme (injectable, IV or nasal) |
| Also called | tirz, tirze, Mounjaro, Zepbound | NAD, nicotinamide adenine dinucleotide |
| FDA status | FDA approved (Mounjaro, Zepbound) | Compounded |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | No WADA record in our data |
| Half-life | approximately 5 dayssubcutaneous · FDA label (Mounjaro) | [half-life by route] |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 | [evidence grade] |
| Human studies we summarised | 24 human (22 randomized or controlled) of 30 summarised | [n] |
| Typical study doses |
| [dose range] |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Not in the letters we track |
The only overlap in PubMed is mouse and cell work
A PubMed title and abstract search on 2 Oct 2026 for NAD+ with tirzepatide matched 3 records: two mouse studies and a cost-effectiveness review. None gave people tirzepatide plus NAD+.
Calculated from pubmed query ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); records matched 3; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
In a mouse model of cisplatin kidney injury, the authors report that tirzepatide boosted NAD+ levels through NAMPT, the rate-limiting enzyme for NAD+ synthesis. This is mouse and cell data.[12]
A mouse Parkinson's model found tirzepatide improved mitochondrial structure and raised ATP content in the substantia nigra.[13]
What human NAD+ trials show
A systematic review found oral NR and NMN consistently showed biochemical target engagement in people, but their functional, metabolic and vascular effects varied and were often absent.[11]
The same review found no outcome trials of injected NAD+ itself for anti-ageing or wellness.[11]
Tirzepatide label and compounding
Per the Zepbound label, delayed gastric emptying from tirzepatide may change how well oral medicines taken alongside it are absorbed.[14]
FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed.[15]
Common questions
Can you take NAD+ and tirzepatide together?
No human study has tested the pair. The review of NAD+ evidence calls clinical effectiveness for wellness outcomes inconclusive.[11]
Does tirzepatide raise NAD levels?
Only in mouse kidney-injury work, where the paper reports tirzepatide boosting NAD+ in cisplatin-injured mice. No human measurement was found.[12]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 9PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
- 12Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD + homeostasis and enhancing Pink1-Parkin-mediated mitophagy.Biochemical pharmacology · 2026PMID 42114682Accessed 2 Oct 2026
- 13GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.International immunopharmacology · 2025PMID 40886502Accessed 2 Oct 2026
- 14ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 15Official web pageOfficial web page · web page
Found an error? Report a correction.